Member Info for stevej

Surprised not to see a RNS this morning so sent an email reminding them they said they were looking forward to keeping shareholders updated holders updated and toxicity should have finished last week.

Will they reply or more importantly, will they acknowledge dosing has completed or first patients at least have finished if staggered via RNS

GLA, exciting times

Thanks PCS1954

Your first one was better than mine yesterday ( didn’t post it 😂), so team work 👏

I will be surprised if we don’t get a dosing complete RNS tomorrow, especially after halting the first trail but also beginning to think that maybe they don’t need to pacify shareholders at this time as they plan to give us very good news within the next week or two.

Just hope they understand positivity is going to help the share price and therefore any negotiations 🤞

GLA

Thanks PCS1954

I copied your data into AI and asked whether Sareum is likely to need the longer review and it suggests and if I’m reading right then they should know main headlines within 2-4 weeks from end of study

Just need a positive confirmation that dosing has finished and no issues encountered in the dosing

AI reply

Based on Sareum’s published Phase 1 data, SDC-1801 (often referred to as Sareum 1801) has a plasma half-life of approximately 17–20 hours in humans. This has been reported consistently by Sareum in multiple updates and was one of the reasons the company concluded that once-daily dosing is feasible.

If you’re considering what this means for a 16-week GLP toxicology study:

* A 17–20 hour half-life is not generally considered exceptionally long in toxicology.

* After dosing stops on Day 112, drug levels would typically decline substantially within about 5–7 half-lives (roughly 4–6 days).

* More than 95% of the drug would usually be eliminated after about 5 half-lives, and over 99% after about 7–10 half-lives, assuming linear kinetics.

Using an 18-hour half-life as an example:

Time after last dose Approximate drug remaining

18 hours 50%

36 hours 25%

72 hours 6.25%

5 days <1%

7 days Trace amounts

Therefore, for SDC-1801, a recovery period of 14–28 days would ordinarily be more than sufficient to assess reversibility of toxicological findings. An extended recovery period of 8–12 weeks would typically be reserved for biologics, compounds with very long half-lives, depot formulations, or situations where delayed toxicity is suspected. Based on the publicly available PK data, SDC-1801 does not appear to fall into that category.

One additional point: Sareum disclosed in 2025 that its previous 16-week GLP toxicology study was stopped because unexpected findings occurred more frequently in control animals than in SDC-1801-treated animals. The company later stated that the findings were considered unrelated to SDC-1801 and that the toxicology program was restarted.

So, if your question is whether SDC-1801’s half-life is long enough to require an unusually lengthy recovery phase after a 16-week tox study, the available evidence suggests no—its reported 17–20 hour half-life is relatively moderate for a once-daily oral small molecule.

Hi EP

It will take time to fully review the data, hence Q4 being mentioned for phase 2 ready status but my feelings is they will get an initial reports on how the study went and potentially feedback from the CRO vast experience.

I think it will be whether Sareum try to maximise the good news or issues out a standard reply to say complete but they did say they were looking forward to keeping us updated

Just my thoughts for what they are worth and everyone needs to make their own decisions on timings as we all are guessing from our own experiences

GLA

100%, we have seen a shortage of shares so getting out now could be very costly next week on news. Many of us have life changing number of shares and been here a while 😂, but believe! This is key in understanding its potential and just a fraction of our values would still be life changing for many. I honestly believe now is our time

GLA

Will we see an updated RNS Monday to say toxicity has concluded with no issues and hopefully that initial reports are extremely encouraging?

They said they would keep us updated, so fingers crossed.

Probably the best possible place to be in this Friday with multiple pending news, here’s to another blue day

GLA

Don’t forget sone warrants were pre consolidation so can’t be exercised until around £3.50 new money for 5 days, so happy to get these exercised 😊

Krone

Sareum don’t show as attending on their website, I’m hoping they are already talking to at least one, hopefully two and would be a good time to release a deal for maximum publicity 🤞

Next week should be interesting as either finished or will finish the toxicity and people will rightly want to be in here after the years of waiting to be where we are now

GLA

25p being paid, can we get close or too 30p today?

Exciting times, GLA

Is that two days running that at 5.05pm 6,000 shares shown as a sell? ( sure it was same yesterday)

Good day today and hopefully more of the same tomorrow, getting exciting now

Next week should also be good as week 16 😊

GLA

Reads well to me

Against this backdrop and the strong scientific and commercial interest in the role of JAK inhibitors in neuroinflammatory diseases, our own collaboration with Receptor.AI is well-positioned. Announced in August 2025, the partnership is focused on accelerating the discovery and optimisation of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors for neuroinflammatory indications, including multiple sclerosis and Parkinson’s disease. The collaboration builds directly on our own preclinical work, where our proprietary Sareum Kinase Inhibitor Library platform identified three TYK2/JAK1 compounds with meaningful BBB penetration which is essential for CNS drug development. Receptor.AI brings to this work a tailored in silico programme, applying virtual screening, generative chemistry, and predictive modelling to identify targets with strong target binding, brain penetration, selectivity, and synthetic feasibility.

Progress within the collaboration has been steady. Following the initiation of lead optimisation work with Receptor.AI in August 2025, the initial rounds of AI-guided design, synthesis and in vitro assay have been completed with further assay work in progress. Sareum retains full ownership of all intellectual property and compounds arising from the collaboration, with no ongoing milestone payments due to Receptor.AI following conclusion of the project.

Beyond the neuroscience programme, our priorities across the portfolio remain unchanged. The Phase 2-enabling toxicology work for SDC-1801 continues to progress, and we are advancing business development discussions around our pipeline of assets.

As the industry’s experience with AI drug discovery deepens I am increasingly confident that our approach represents both sound science and sound strategy. Combining our deep TYK2 chemistry knowledge and clinical-stage expertise with Receptor.AI’s generative and predictive capabilities gives us access to tools that will help streamline the often-lengthy drug discovery and development process.

Thank you, as always, for your continued support and engagement.

Dr Stephen Parker,

Executive Chairman,

Sareum Holdings plc

1 of 2

Dear Shareholders,

This month, I have been reflecting on our portfolio structure and the recent activities we have undertaken to maintain a diversified pipeline, such as our CNS programme. I want to take the opportunity to look in more detail into our artificial intelligence (AI) collaboration with Receptor.AI, announced last August and the recent activity within the sector. While our key focus has been on the ongoing Phase 2-enabling toxicology programme for SDC-1801, meaningful progress has been made on our neuroscience discovery effort and I think the wider context for AI-driven drug discovery makes this increasingly compelling.

The application of AI to drug discovery has moved rapidly from concept to clinical reality. Earlier this year, Insilico Medicine reported positive Phase IIa data for Rentosertib, a small molecule TNIK inhibitor for idiopathic pulmonary fibrosis that was discovered using a generative AI platform. This is widely regarded as the first clinical proof-of-concept for a fully AI-originated drug.[1][2] In parallel, the breadth and scale of AI collaboration activity across the sector continues to grow and AI is becoming embedded into the discovery engines of many large pharma companies.

Incyte, the $19 billion biopharma, recently signed expanded R&D agreements with two AI-focused startups, Genesis Molecular AI and Edison Scientific.[3] Incyte’s rationale centred not just on AI’s speed but also on the value of feeding its proprietary experimental data into AI models to improve their predictive power, a parallel to Sareum, where our deep TYK2 chemistry dataset represents a meaningful asset in our collaboration with Receptor.AI. Several other significant AI drug discovery deals have emerged including Eli Lilly’s $2.75 billion deal with Insilico Medicine and GSK’s $50 million deal with AI biotech, Noetik, for access to their proprietary lung and colon cancer models. Overall, these recent developments represent a shift in how early-stage drug discovery is conducted, and one that companies of all sizes are moving quickly to embrace.

Got to be a sell as money men probably need shares, no value though 😂

Maybe a tick up tomorrow morning even without news 🤞

Looks like a late trade @5.05pm for 20.50, can’t see how many yet but should show in 10 minutes 🤔

Bailiff

I like your thinking 🤣🤔😊, do wonder if we will see some late trades or a RNS in the morning as long overdue 🤞

GLA

Bailiff,

Similar to you, mine was 1st trade of day for only 4,800 ish, just feel even the little ones will pay dividends on news

GLA

20.65 are buys as I bought a few earlier today at this rate.

He needs to get on with May’s as only a few days left, bet he dreads going every month now 😂

What will the topic be this month, hopefully touch on us being in week 15 of tox studies

GLA

Des

Agree this could be the case but also expect with their expertise that they can also give a good indication on how the test went, especially against similar tests on other compounds at the current stage. I’m sure they are continuously reviewing data to date. ( just my thoughts )

GLA